Project Details
Description
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)
Status | Active |
---|---|
Effective start/end date | 9/1/21 → 9/1/23 |
Funding
- Vertex Pharmaceuticals Incorporated
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.